|
90 Companies |
|
65 Products |
|
65 Products |
|
50 Mechanisms of Action |
|
828 Trials |
|
64398 News |
|
| «12...695696697698699700701702703704705...723724» |
- Enrollment closed, Enrollment change: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging (clinicaltrials.gov) - Aug 10, 2016
P1, N=1009, Active, not recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | N=1500 --> 1009
- Trial primary completion date, Surgery: Proteomic Profiles in Trabeculectomy Patients (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=120, Recruiting, Sponsor: Singapore National Eye Centre
Recruiting --> Active, not recruiting | N=1500 --> 1009 Trial primary completion date: Mar 2017 --> Mar 2018
- New trial: Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=25, Recruiting, Sponsor: EyeSonix
- | travoprost (ENV-515) / Envisia Therap
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma (clinicaltrials.gov) - Aug 5, 2016
P2a, N=36, Active, not recruiting, Sponsor: Envisia Therapeutics
Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=20 --> 36 | Trial primary completion date: Sep 2015 --> Oct 2017
- ||| Sentinel (cenegermin-bkbj) / Dompe
New P1 trial: Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma (clinicaltrials.gov) - Aug 4, 2016
P1, N=60, Not yet recruiting, Sponsor: Domp
- Trial completion, Enrollment change: Clinical and Molecular Studies in Families With Glaucoma and Related Diseases (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=1, Completed, Sponsor: National Eye Institute (NEI)
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=20 --> 36 | Trial primary completion date: Sep 2015 --> Oct 2017 Recruiting --> Completed | N=2000 --> 1
- dorzolamide / Generic mfg., timolol maleate ophthalmic solution / Generic mfg.
New P1 trial: Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses (clinicaltrials.gov) - Aug 2, 2016
P1, N=50, Not yet recruiting, Sponsor: University of Florida
- ||| Trial completion, HEOR: How Has Glaucoma Affected Your Quality of Life? (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=163, Completed, Sponsor: Wills Eye
Recruiting --> Completed | N=2000 --> 1 Active, not recruiting --> Completed
- Trial primary completion date: Macular Damage in Early Glaucoma and Progression (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=375, Recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Trial primary completion date: Dec 2020 --> Dec 2018
- || Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Trial primary completion date: SIMBRINZA (clinicaltrials.gov) - Jul 27, 2016
P4, N=280, Recruiting, Sponsor: Alcon Research
Trial primary completion date: Dec 2020 --> Dec 2018 Trial primary completion date: Nov 2016 --> Feb 2017
- pilocarpine / Generic mfg.
Enrollment open: The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=30, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Nov 2016 --> Feb 2017 Not yet recruiting --> Recruiting
- dexmedetomidine / Generic mfg.
Surgery: Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=105, Not yet recruiting, Sponsor: Cairo University
- ||||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Enrollment closed: Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) (clinicaltrials.gov) - Jul 23, 2016
P3, N=376, Active, not recruiting, Sponsor: Alcon Research
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New trial, Surgery: Aqueous Dynamics and Glaucoma Surgeries (clinicaltrials.gov) - Jul 21, 2016
P=N/A, N=100, Recruiting, Sponsor: Guy's and St Thomas' NHS Foundation Trust
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, Trial completion: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jul 20, 2016
P3, N=272, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety of GANFORT (clinicaltrials.gov) - Jul 19, 2016
P4, N=750, Recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Sep 2017
- |||| Rhopressa (netarsudil) / Aerie Pharma
Clinical: Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 19, 2016
P3, N=240, Active, not recruiting, Sponsor: Aerie Pharmaceuticals
Trial primary completion date: Nov 2016 --> Sep 2017 Trial primary completion date: May 2016 --> Nov 2016
- New trial, Surgery: FEMTOHTO: Effect of Elevated Intraocular Pressure in Glaucoma Patients During Femtolaser Cataract Surgery (clinicaltrials.gov) - Jul 18, 2016
P=N/A, N=260, Recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- ||||||| Rhopressa (netarsudil) / Aerie Pharma
Clinical: Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension (clinicaltrials.gov) - Jul 13, 2016
P3, N=756, Completed, Sponsor: Aerie Pharmaceuticals
Trial primary completion date: May 2016 --> Nov 2016 Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2016
- New trial: Analysis of Translaminar Pressure Gradient Using Noninvasive Cerebrospinal Fluid Pressure Monitoring (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=200, Enrolling by invitation, Sponsor: University of Miami
- ||||| trabodenoson/latanoprost / Rocket Pharma, trabodenoson (INO-8875) / Rocket Pharma
New P2 trial: Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG (clinicaltrials.gov) - Jul 12, 2016
P2, N=165, Not yet recruiting, Sponsor: Inotek Pharmaceuticals Corporation
- ||| New trial, Real-world evidence, Real-world: STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program (clinicaltrials.gov) - Jul 7, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: iSTAR Medical
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema (clinicaltrials.gov) - Jul 6, 2016
P2, N=10, Completed, Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2016 Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Feb 2013 --> Jun 2014
- New trial: The EASE Study - Human Factor and Usability Testing of a Binocular OCT System (clinicaltrials.gov) - Jul 5, 2016
P=N/A, N=45, Recruiting, Sponsor: University College, London
- |||||||||| Omlonti (omidenepag isopropyl) / Santen, Ube Corp
New P3 trial, Monotherapy: A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study (clinicaltrials.gov) - Jul 5, 2016
P3, N=120, Recruiting, Sponsor: Santen Pharmaceutical Co., Ltd.
- ||| Omlonti (omidenepag isopropyl) / Santen, Ube Corp
New P3 trial: A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study (clinicaltrials.gov) - Jul 5, 2016
P3, N=30, Recruiting, Sponsor: Santen Pharmaceutical Co., Ltd.
- ||| Enrollment open: Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1) (clinicaltrials.gov) - Jun 28, 2016
P=N/A, N=249, Recruiting, Sponsor: Heidelberg Engineering GmbH
Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Feb 2013 --> Jun 2014 Not yet recruiting --> Recruiting
- ||| Enrollment open: Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3) (clinicaltrials.gov) - Jun 28, 2016
P=N/A, N=249, Recruiting, Sponsor: Heidelberg Engineering GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Enrollment closed: VEGA: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (clinicaltrials.gov) - Jun 27, 2016
P3, N=54, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment status: The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS) (clinicaltrials.gov) - Jun 24, 2016
P4, N=280, Recruiting, Sponsor: Robert Feldman
Recruiting --> Active, not recruiting Enrolling by invitation --> Recruiting
- Trial primary completion date: The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants (clinicaltrials.gov) - Jun 22, 2016
P=N/A, N=50, Recruiting, Sponsor: Duke University
Enrolling by invitation --> Recruiting Trial primary completion date: Apr 2016 --> Jan 2017
- New trial: The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal Micro-structure (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=440, Not yet recruiting, Sponsor: Sheba Medical Center
- |||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Enrollment open: Safety and Efficacy of SIMBRINZA (clinicaltrials.gov) - Jun 20, 2016
P4, N=300, Recruiting, Sponsor: Alcon Research
Trial primary completion date: Apr 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- | latanoprost liposomal (POLAT 001) / Avid Bioservices
Trial completion: Open Label Extension of LipoLat-CS202 (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=17, Completed, Sponsor: Peregrine Ophthalmic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New trial: Associations of Vitamin D Receptor ApaI and Tru9I Polymorphisms With the Risk of Primary Open-angle Glaucoma (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=200, Completed, Sponsor: Lv Yingjuan
- | mitomycin / Generic mfg.
New P2 trial, Surgery: AMCT: Ahmed Glaucoma Valve Surgery With Mitomycin-C (clinicaltrials.gov) - Jun 18, 2016
P2, N=100, Not yet recruiting, Sponsor: University of California, San Francisco
- |||||||||| latanoprost / Generic mfg.
New P3 trial, Head-to-Head, Compliance: Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno (clinicaltrials.gov) - Jun 16, 2016
P3, N=100, Recruiting, Sponsor: Laboratorios Sophia S.A de C.V.
- Zioptan (tafluprost) / Santen, Merck (MSD)
New P4 trial: 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (clinicaltrials.gov) - Jun 16, 2016
P4, N=43, Completed, Sponsor: Aristotle University Of Thessaloniki
- Enrollment open: POSAG: Prevalence of Obstructive Sleep Apnoea in Glaucoma (clinicaltrials.gov) - Jun 15, 2016
P=N/A, N=480, Recruiting, Sponsor: Papworth Hospital NHS Foundation Trust
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | travoprost ophthalmic / Generic mfg.
New P4 trial: Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jun 11, 2016
P4, N=76, Not yet recruiting, Sponsor: Universit
- Trial completion, Trial primary completion date: Does Oral Acetaminophen Lower Intraocular Pressure? (clinicaltrials.gov) - Jun 10, 2016
P0, N=11, Completed, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2016
- timolol maleate ophthalmic solution / Generic mfg.
Enrollment open: Evaluation of a New Method for Instilling Eye Drops (clinicaltrials.gov) - Jun 9, 2016
P0, N=60, Recruiting, Sponsor: University of Waterloo
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2016 Not yet recruiting --> Recruiting
- ||||| latanoprost / Generic mfg.
New P4 trial: A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma (clinicaltrials.gov) - Jun 9, 2016
P4, N=60, Recruiting, Sponsor: Dr. David Yan
- ||||| New P4 trial: Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients (clinicaltrials.gov) - Jun 2, 2016
P4, N=80, Not yet recruiting, Sponsor: EyeTechCare
- Enrollment open, Trial initiation date, Trial primary completion date: AUREVI 1: AUgmented REality for the Visually Impaired - Part 1 (clinicaltrials.gov) - Jun 1, 2016
P=N/A, N=15, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> May 2016 | Trial primary completion date: Oct 2017 --> May 2017
- |||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Enrollment open: 24-hr Intraocular Pressure Control With SIMBRINZA (clinicaltrials.gov) - May 31, 2016
P4, N=142, Recruiting, Sponsor: Alcon Research
Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> May 2016 | Trial primary completion date: Oct 2017 --> May 2017 Not yet recruiting --> Recruiting
- New trial: A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction (clinicaltrials.gov) - May 27, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: New World Medical, Inc.
- ||| New trial: Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1) (clinicaltrials.gov) - May 27, 2016
P=N/A, N=249, Not yet recruiting, Sponsor: Heidelberg Engineering GmbH
- ||| New trial: Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3) (clinicaltrials.gov) - May 27, 2016
P=N/A, N=249, Not yet recruiting, Sponsor: Heidelberg Engineering GmbH
- Trial primary completion date: Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration (clinicaltrials.gov) - May 26, 2016
P1/2, N=16, Enrolling by invitation, Sponsor: Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Nov 2017